Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/70324
Type
ArticleCopyright
Restricted access
Embargo date
2030-12-31
Collections
Metadata
Show full item record
STRUCTURAL DESIGN, SYNTHESIS AND ANTI-TRYPANOSOMA CRUZI PROFILE OF THE SECOND GENERATION OF 4-THIAZOLIDINONES CHLORINE DERIVATIVES
Author
Oliveira Filho, Gevanio Bezerra de
Cardoso, Marcos Veríssimo de Oliveira
Santos, Aline Caroline da Silva
Santos, Thiago André Ramos dos
Cristovão-Silva, Ana Catarina
Rubio, Laura González
Maia Neto, Luiz da Silva
Leite, Paulo Gaio
Machado, Fabiana Simão
Alves, Luiz Carlos
Brayner, Fabio André
Pereira, Valéria Rêgo Alves
Leite, Ana Cristina Lima
Cardoso, Marcos Veríssimo de Oliveira
Santos, Aline Caroline da Silva
Santos, Thiago André Ramos dos
Cristovão-Silva, Ana Catarina
Rubio, Laura González
Maia Neto, Luiz da Silva
Leite, Paulo Gaio
Machado, Fabiana Simão
Alves, Luiz Carlos
Brayner, Fabio André
Pereira, Valéria Rêgo Alves
Leite, Ana Cristina Lima
Affilliation
Federal University of Pernambuco. Health Sciences Center. Department of Pharmaceutical Sciences. Recife, PE, Brazil.
University of Pernambuco. Laboratory of Prospecting Bioactive Molecules. Petrolina, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Laboratório de Imunopatologia e Biologia Molecular. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Laboratório de Imunopatologia e Biologia Molecular. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Laboratório de Imunopatologia e Biologia Molecular. Recife, PE, Brasil.
Federal University of Pernambuco. Health Sciences Center. Department of Pharmaceutical Sciences. Recife, PE, Brazil.
Federal University of Pernambuco. Health Sciences Center. Department of Pharmaceutical Sciences. Recife, PE, Brazil.
Federal University of Minas Gerais. Institute of Biological Sciences. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil.
Federal University of Minas Gerais. Institute of Biological Sciences. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil.
Universidade Federal de Pernambuco. Instituto Keizo Asami. Laboratório de Imunopatologia Keizo Asami. Recife, PE, Brasil / Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Parasitologia. Laboratórios de Biologia Celular e Molecular, Leishmaniose e Mutagênese. Recife, PE, Brasil.
Universidade Federal de Pernambuco. Instituto Keizo Asami. Laboratório de Imunopatologia Keizo Asami. Recife, PE, Brasil / Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Parasitologia. Laboratórios de Biologia Celular e Molecular, Leishmaniose e Mutagênese. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Laboratório de Imunopatologia e Biologia Molecular. Recife, PE, Brasil.
Federal University of Pernambuco. Health Sciences Center. Department of Pharmaceutical Sciences. Recife, PE, Brazil.
University of Pernambuco. Laboratory of Prospecting Bioactive Molecules. Petrolina, PE, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Laboratório de Imunopatologia e Biologia Molecular. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Laboratório de Imunopatologia e Biologia Molecular. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Laboratório de Imunopatologia e Biologia Molecular. Recife, PE, Brasil.
Federal University of Pernambuco. Health Sciences Center. Department of Pharmaceutical Sciences. Recife, PE, Brazil.
Federal University of Pernambuco. Health Sciences Center. Department of Pharmaceutical Sciences. Recife, PE, Brazil.
Federal University of Minas Gerais. Institute of Biological Sciences. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil.
Federal University of Minas Gerais. Institute of Biological Sciences. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil.
Universidade Federal de Pernambuco. Instituto Keizo Asami. Laboratório de Imunopatologia Keizo Asami. Recife, PE, Brasil / Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Parasitologia. Laboratórios de Biologia Celular e Molecular, Leishmaniose e Mutagênese. Recife, PE, Brasil.
Universidade Federal de Pernambuco. Instituto Keizo Asami. Laboratório de Imunopatologia Keizo Asami. Recife, PE, Brasil / Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Parasitologia. Laboratórios de Biologia Celular e Molecular, Leishmaniose e Mutagênese. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Imunologia. Laboratório de Imunopatologia e Biologia Molecular. Recife, PE, Brasil.
Federal University of Pernambuco. Health Sciences Center. Department of Pharmaceutical Sciences. Recife, PE, Brazil.
Abstract
Chagas disease causes more deaths in the Americas than any other parasitic disease. Initially confined to the American continent, it is increasingly becoming a global health problem. In fact, it is considered to be an "exotic" disease in Europe, being virtually undiagnosed. Benznidazole, the only drug approved for treatment, effectively treats acute-stage Chagas disease, but its effectiveness for treating indeterminate and chronic stages remains uncertain. Previously, our research group demonstrated that 4-thiazolidinones presented anti-T. cruzi activity including in the in vivo assays in mice, making this fragment appealing for drug development. The present work reports the synthesis and anti-T. cruzi activities of a novel series of 4-thiazolidinones derivatives that resulted in an increased anti-T. cruzi activity in comparison to thiosemicarbazones intermediates. Compounds 2c, 2e, and 3a showed potent inhibition of the trypomastigote form of the parasite at low cytotoxicity concentrations in mouse splenocytes. Besides, all the 2c, 2e, and 3a tested concentrations showed no cytotoxic activity on macrophages cell viability. When macrophages were submitted to T. cruzi infection and treated with 2c and 3a, compounds reduced the release of trypomastigote forms. Results also showed that the increased trypanocidal activity induced by 2c and 3a is independent of nitric oxide release. Flow cytometry assay showed that compound 2e was able to induce necrosis and apoptosis in trypomastigotes. Parasites treated with the compounds 2e, 3a, and 3c presented flagellum shortening, retraction and curvature of the parasite body, and extravasation of the internal content. Together, these data revealed a novel series of 4-thiazolidinones fragment-based compounds with potential effects against T. cruzi and lead-like characteristics.
Share